25 May 2013
Keywords: epistem, loss, rises, enters, novartis, deal, uk-based
Article | 23 March 2009
UK-based Epistem, a company utilizing contract research revenue to fund the development of novel therapies based on epithelial stem cell
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 March 2009
16 March 2009
24 May 2013
© 2013 thepharmaletter.com